Riley J. Mangan's OpenAlex record shows 47 works with ~1,074 total citations and an h-index of 13, with a steep recent trajectory: 427 citations in 2024 and 211 in 2025, driven largely by resource papers . The Semantic Scholar view (h-index 7, 227 citations, 16 papers) is narrower, illustrating how author-level metrics vary substantially across databases depending on indexing and name disambiguation.
Mangan's signature work is a first-author Cell paper showing that adaptive sequence divergence forged new human neurodevelopmental enhancers, applying Enformer deep learning across 34 haplotypes from modern humans, archaic hominins, and great apes to predict 37,592 lineage-specific cis-regulatory events; luciferase assays in neural stem/progenitor cells validated predictions (9/15 elements active; predicted-versus-observed Pearson R = 0.81), and reciprocal mutagenesis showed a single derived allele creating an SRF motif is necessary and sufficient for a hominin-specific enhancer . Mangan also co-authored the GENCODE 2025 reference annotation (394 citations) and the Nature ape genome sequencing paper (142 citations) , plus a 2025 Cell paper on single-cell epigenomic rewiring in Alzheimer's disease profiling 3.5 million cells from 384 postmortem samples .
Earlier work includes infant HIV/SIV immunology in rhesus macaques (maternal bNAb selection of resistant variants, breast-milk antibody studies) and cancer biology (TGFΞ² signaling in pancreatic and colon cancer). The 2026 circadian breast cancer preprintβtime-resolved single-nucleus multiome of 101,321 nuclei across four circadian time points, with cross-species validation in 76 human TNBC samplesβproposes epithelial-immune circadian misalignment as a mechanism of immune evasion and chronotherapy target, though it lacks spatial transcriptomics, prospective human interventional data, and must bridge nocturnal mouse to diurnal human circadian biology .
Mangan demonstrates unusual breadth: rigorous experimental validation (luciferase assays, reciprocal mutagenesis) alongside computational methods development (the Gonomics Go library for genomics ). The 2026 preprint discloses research funding from Lilly, Pfizer, and Novartis and advisory roles at GE Healthcare and Carrick Therapeuticsβindustry entanglements worth noting when evaluating chronotherapy-adjacent claims . Key uncertainties: the deep-learning linCRE approach depends on Enformer's accuracy in untested cellular contexts (validated in only NSPCs), and the enrichment effect near human-upregulated DEGs is modest (log2 enrichment = 0.13) . Overall, this is an early-career (postdoctoral-stage) scientist with a first-author Cell paper, co-authorships on flagship community resources, growing visibility, and a trajectory consistent with continued high-impact workβconfidence in this assessment is moderate given limited independent bibliometric verification.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.